MARATTO

article · International Journal of Pharmacology

Perindopril Alleviates Inflammation via Cyclooxygenase Inhibition: A Bioinformatics, in vitro and in vivo Evaluation

Abstract

Background and Objective: Perindopril (PER), an angiotensin-converting enzyme (ACE) inhibitor with anti-apoptotic, antioxidant and anti-inflammatory characteristics, has long been used to treat cardiovascular illnesses.In this study, the enzyme inhibitory activity of PER against Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) was determined.Materials and Methods: The PERʼs anti-inflammatory actions were estimated by in vitro COX-1 and COX-2 inhibition assays, the in vivo rat model of carrageenan-induced paw edema, histopathological examination, molecular modeling, docking and molecular dynamics studies.The data were analyzed using the Analysis of Variance (ANOVA) Test.Results: The PER IC 50 values for COX-1 and COX-2 were calculated to be 8.3 and 0.1 µM, respectively, showing that PER has an 85.5-fold higher affinity for COX-2 than for COX-1.The PER was found to be a moderate inflammation suppressor in rat paw assay, comparable to celecoxib and indomethacin.Docking and molecular dynamics (MD) simulation supported the stable binding of PER with COX-2.Conclusion: Current findings revealed that PER can be used for local acute inflammation and utilized as a substitute for other topical anti-inflammatory medicines, particularly those containing steroids.

Research topics

  • Inflammatory mediators and NSAID effects
  • Hormonal Regulation and Hypertension
  • Eicosanoids and Hypertension Pharmacology

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.3923/ijp.2023.428.438

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.